Cost-effectiveness of low-dose computed tomography for lung cancer screening in India: A Markov modelling study
Journal of Medical Screening · 2026-03 · 33 (1) · 15-24
DOI: 10.1177/09691413251360969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Screening, online erschienen am 22.07.2025. Verfasst von Gowthaman Thangavel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Indian Council of Medical Research, National Centre for Disease Informatics and Research, Bengaluru, India. Hauptthemen laut MEDLINE: Lung Neoplasms, Cost-Benefit Analysis, Tomography, X-Ray Computed, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Lung cancer is a leading cause of cancer-related mortality in India, with most cases diagnosed at advanced stages. Low-dose computed tomography (LDCT) screening has been shown to enhance early detection and improve survival rates, but its cost-effectiveness in India remains unclear.
Objective
To evaluate the cost-effectiveness of LDCT screening for lung cancer compared to chest X-ray (CXR) and no screening in India using a Markov model.
Methods
A Markov model simulated the natural progression of lung cancer, comparing LDCT, CXR, and no screening in a high-risk hypothetical population in the age group of 30 to 65 years. The model incorporated transition probabilities, costs, and quality-adjusted life years (QALYs) with data from published literature, cancer registries, and Global Cancer Observatory. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB). Sensitivity analyses, including probabilistic sensitivity analysis, threshold analysis, and budget impact, were conducted to evaluate model robustness.
Results
LDCT screening yielded the highest effectiveness (23.71 QALYs), compared to 19.82 for CXR and 13.43 for no screening. Although LDCT incurred the highest cost (₹380064.75), it also provided the highest NMB (₹5232241.18), making it the most cost-effective option. The ICER for LDCT (₹36429.44) remained below the willingness-to-pay threshold, confirming its economic viability. Sensitivity analyses further validated LDCT's robustness across scenarios.
Conclusion
LDCT is a cost-effective strategy for lung cancer screening in India, offering significant health benefits despite higher costs. Policymakers should consider integrating LDCT into national cancer screening programs, with further research needed to optimise screening intervals and target populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Indian Council of Medical Research, National Centre for Disease Informatics and Research, Bengaluru, India.
ORCID-Profile: Gowthaman Thangavel, Stany Mathew, Praveen Pujar, Anita Nath
Zitieren
APA
Thangavel, G., Mathew, S., Pujar, P., & Nath, A. (2026). Cost-effectiveness of low-dose computed tomography for lung cancer screening in India: A Markov modelling study. Journal of Medical Screening, 33(1), 15-24. https://doi.org/10.1177/09691413251360969
Vancouver
Thangavel G, Mathew S, Pujar P, Nath A. Cost-effectiveness of low-dose computed tomography for lung cancer screening in India: A Markov modelling study. Journal of Medical Screening. 2026;33(1):15-24. doi:10.1177/09691413251360969
BibTeX
@article{Thangavel2026,
author = {Thangavel, Gowthaman and Mathew, Stany and Pujar, Praveen and Nath, Anita},
title = {Cost-effectiveness of low-dose computed tomography for lung cancer screening in India: A Markov modelling study},
journal = {Journal of Medical Screening},
year = {2026},
volume = {33},
number = {1},
pages = {15--24},
doi = {10.1177/09691413251360969}
}
EUVIMED